{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:38:59Z","timestamp":1790681939290,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Worldwide, the number of cancer survivors is rapidly increasing. The aim of this study was to quantify long-term health service costs of cancer survivorship on a population level. The study cohort comprised residents of Queensland, Australia, diagnosed with a first primary malignancy between 1997 and 2015. Administrative databases were linked with cancer registry records to capture all health service utilization. Health service costs between 2013\u20132016 were analyzed using a bottom-up costing approach. The cumulative mean annual healthcare expenditure (2013\u20132016) for the cohort of N = 230,380 individuals was AU$3.66 billion. The highest costs were incurred by patients with a history of prostate (AU$538 m), breast (AU$496 m) or colorectal (AU$476 m) cancers. Costs by time since diagnosis were typically highest in the first year after diagnosis and decreased over time. Overall mean annual healthcare costs per person (2013\u20132016) were AU$15,889 (SD: AU$25,065) and highest costs per individual were for myeloma (AU$45,951), brain (AU$30,264) or liver cancer (AU$29,619) patients. Our results inform policy makers in Australia of the long-term health service costs of cancer survivors, provide data for economic evaluations and reinforce the benefits of investing in cancer prevention.<\/jats:p>","DOI":"10.3390\/ijerph19159473","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T21:41:37Z","timestamp":1659476497000},"page":"9473","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cancer Survivors\u2019 Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q)"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1369-7663","authenticated-orcid":false,"given":"Katharina M. D.","family":"Merollini","sequence":"first","affiliation":[{"name":"School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore, QLD 4558, Australia"},{"name":"Sunshine Coast Health Institute, Birtinya, QLD 4575, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-4249","authenticated-orcid":false,"given":"Louisa G.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Health Economics, Population Health Department, QIMR Berghofer Medical Research Institute, Herston, QLD 4006, Australia"},{"name":"School of Public Health, The University of Queensland, Herston, QLD 4006, Australia"},{"name":"School of Biomedical Sciences, Queensland University of Technology, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-3317","authenticated-orcid":false,"given":"Yiu M.","family":"Ho","sequence":"additional","affiliation":[{"name":"Rockhampton Hospital, Central Queensland Hospital and Health Service, Rockhampton, QLD 4700, Australia"},{"name":"Rural Clinical School, The University of Queensland, Rockhampton, QLD 4700, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne F.","family":"Aitken","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Queensland, Herston, QLD 4006, Australia"},{"name":"Cancer Council Queensland, Fortitude Valley, QLD 4006, Australia"},{"name":"School of Public Health and Social Work, Queensland University of Technology, Kelvin Grove, QLD 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kimlin","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Queensland University of Technology, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.6004\/jnccn.2014.0005","article-title":"Survivorship: Introduction and definition. Clinical practice guidelines in oncology","volume":"12","author":"Denlinger","year":"2014","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1200\/JCO.2016.68.3870","article-title":"Categorization of Cancer Survivors: Why We Need It","volume":"34","author":"Surbone","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","article-title":"Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019","volume":"8","author":"Kocarnik","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_5","unstructured":"Australian Institute of Health and Welfare (2021). Cancer in Australia 2021. Cancer Series No. 133 (Cat. No. CAN 144), AIHW, ed., Australian Government."},{"key":"ref_6","unstructured":"Australian Institute of Health and Welfare (2021). Disease Expenditure in Australia 2018-19, v23.0 (Last Updated 18\/02\/22) ed., Australian Government, Ed. AIHW."},{"key":"ref_7","unstructured":"Australian Institute of Health and Welfare (2021). Health and Welfare. Health system expenditure on cancer and other neoplasms in Australia, 2015\u20132016. Cancer Series No. 131 (Cat. No. CAN 142), AIHW, ed., Australian Government."},{"key":"ref_8","unstructured":"American Cancer Society (2019). Cancer Treatment & Survivorship: Facts & Figures 2019\u20132021, American Cancer Society."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1017\/S2045796019000866","article-title":"Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions","volume":"29","author":"Caruso","year":"2020","journal-title":"Epidemiol. Psychiatr Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin. Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3857\/roj.2020.00213","article-title":"Late side effects of radiation treatment for head and neck cancer","volume":"38","author":"Brook","year":"2020","journal-title":"Radiat. Oncol. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.brachy.2021.03.014","article-title":"Acute and late side-effects after low dose-rate brachytherapy for prostate cancer; incidence, management and technical considerations","volume":"20","author":"Helou","year":"2021","journal-title":"Brachytherapy"},{"key":"ref_13","first-page":"579","article-title":"The impact of chronic conditions on the economic burden of cancer survivorship: A systematic review","volume":"16","author":"Rim","year":"2016","journal-title":"Expert Rev. Pharm. Outcomes Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/JCO.2013.49.1241","article-title":"Economic burden of cancer survivorship among adults in the United States","volume":"31","author":"Guy","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40258-020-00619-z","article-title":"The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review","volume":"19","author":"Iragorri","year":"2021","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ajco.13180","article-title":"The patient co-payment and opportunity costs of accessing healthcare for Indigenous Australians with cancer: A whole of population data linkage study","volume":"15","author":"Callander","year":"2019","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13561-019-0219-9","article-title":"Correction to: CancerCostMod: A model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients","volume":"9","author":"Bates","year":"2019","journal-title":"Health Econ. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12939-019-0931-4","article-title":"Long-term out of pocket expenditure of people with cancer: Comparing health service cost and use for indigenous and non-indigenous people with cancer in Australia","volume":"18","author":"Callander","year":"2019","journal-title":"Int. J. Equity Health"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Goldsbury, D.E., Yap, S., Weber, M.F., Veerman, L., Rankin, N., Banks, E., Canfell, K., and O\u2019Connell, D.L. (2018). Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201552"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s11255-017-1669-9","article-title":"Long-term costs and survival of prostate cancer: A population-based study","volume":"49","author":"Brodszky","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e213800","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin in the Veterans Affairs Health System","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10198-021-01315-y","article-title":"Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis","volume":"22","author":"Grady","year":"2021","journal-title":"Eur. J. Health Econ."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ejhpharm-2017-001453","article-title":"The economic burden of metastatic breast cancer in Spain","volume":"27","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.9778\/cmajo.20170144","article-title":"The economic burden of cancer care in Canada: A population-based cost study","volume":"6","author":"Weir","year":"2018","journal-title":"CMAJ Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13561-021-00322-2","article-title":"Economic burden of lung cancer in Turkey: A cost of illness study from payer perspective","volume":"11","author":"Cicin","year":"2021","journal-title":"Health Econ. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2468-1253(21)00147-3","article-title":"The economic burden of colorectal cancer across Europe: A population-based cost-of-illness study","volume":"6","author":"Henderson","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic Burden of Bladder Cancer Across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Watanabe, T., Goto, R., Yamamoto, Y., Ichinose, Y., and Higashi, T. (2021). First-Year Healthcare Resource Utilization Costs of Five Major Cancers in Japan. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18189447"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10198-018-0986-y","article-title":"The economic burden of disease of epithelial ovarian cancer in Spain: The OvarCost study","volume":"20","author":"Borras","year":"2019","journal-title":"Eur. J. Health Econ."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10198-008-0101-x","article-title":"Comparing methodologies for the cost estimation of hospital services","volume":"10","author":"Tan","year":"2009","journal-title":"Eur. J. Health Econ."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10552-007-9033-5","article-title":"Health behaviors of cancer survivors: Data from an Australian population-based survey","volume":"18","author":"Eakin","year":"2007","journal-title":"Cancer Causes Control."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wong, W., Yim, Y.M., Kim, A., Cloutier, M., Gauthier-Loiselle, M., Gagnon-Sanschagrin, P., and Guerin, A. (2018). Assessment of costs associated with adverse events in patients with cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196007"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Merollini, K.M.D., Gordon, L.G., Aitken, J.F., and Kimlin, M.G. (2020). Lifetime Costs of Surviving Cancer-A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17082831"},{"key":"ref_34","unstructured":"(2022, June 21). Australian Bureau of Statistics. National, State and Territory Population, Available online: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.healthpol.2020.08.012","article-title":"Horizontal inequity in the utilisation of healthcare services in Australia","volume":"124","author":"Pulok","year":"2020","journal-title":"Health Policy"},{"key":"ref_36","unstructured":"Duckett, S. (2004). The Australian Health Care System, Oxford University Press."},{"key":"ref_37","unstructured":"World Health Organisation (2000). International Classification of Diseases for Oncology, WHO. [3rd ed.]. (ICD-O3)."},{"key":"ref_38","unstructured":"Australian Government, C.A. (2021, December 01). National Cancer Control Indicator: 5-Year Relative Survival, Available online: https:\/\/ncci.canceraustralia.gov.au\/outcomes\/relative-survival-rate\/5-year-relative-survival."},{"key":"ref_39","unstructured":"(2021, December 01). Nuffield Trust. Cancer Survival Rates. Available online: https:\/\/www.nuffieldtrust.org.uk\/resource\/cancer-survival-rates."},{"key":"ref_40","unstructured":"Australian Bureau of Statistics (2016). Standard Australian Classification of Countries (SACC), Australian Bureau of Statistics."},{"key":"ref_41","unstructured":"Cancer Council NSW, and Understanding Myeloma (2020). A Guide for People with Cancer, Their Families and Friends, Cancer Council NSW."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13561-018-0212-8","article-title":"Cancer Cost Mod: A model of the healthcare expenditure, patient resource use, and patient co-payment costs for Australian cancer patients","volume":"8","author":"Bates","year":"2018","journal-title":"Health Econ. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"de Oliveira, C., Pataky, R., Bremner, K.E., Rangrej, J., Chan, K.K., Cheung, W.Y., Hoch, J.S., Peacock, S., and Krahn, M.D. (2016). Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2835-7"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3747\/co.26.4399","article-title":"A population-level comparison of cancer-related and non-cancer-related health care costs using publicly available provincial administrative data","volume":"26","author":"Sam","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/pon.5516","article-title":"The psychosocial cost burden of cancer: A systematic literature review","volume":"29","author":"Essue","year":"2020","journal-title":"Psychooncology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","article-title":"Economic burden of cancer across the European Union: A population-based cost analysis","volume":"14","author":"Leal","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/1467-9566.12830","article-title":"\u2018Treat them into the grave\u2019: Cancer physicians\u2019 attitudes towards the use of high-cost cancer medicines at the end of life","volume":"41","author":"Wiersma","year":"2019","journal-title":"Sociol. Health Illn."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/15\/9473\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:01:16Z","timestamp":1760140876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/15\/9473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":47,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijerph19159473"],"URL":"https:\/\/doi.org\/10.3390\/ijerph19159473","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]}}}